Dipna Pharmachem has informed that pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the exchange has issued In-principle approval vide Ref: LOD/RIGHT/CP/FIP/1109/2023-24 dated 17th January, 2024 for the proposed rights issue. The In-principle approval letter received from the Stock Exchange i.e. BSE is enclosed.
The above information is a part of company’s filings submitted to BSE.